Squarepoint Ops LLC Sells 24,966 Shares of Surmodics, Inc. $SRDX

Squarepoint Ops LLC trimmed its holdings in Surmodics, Inc. (NASDAQ:SRDX) by 24.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 75,595 shares of the company’s stock after selling 24,966 shares during the period. Squarepoint Ops LLC owned about 0.53% of Surmodics worth $2,246,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of SRDX. BNP Paribas Financial Markets grew its position in shares of Surmodics by 67.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company’s stock valued at $43,000 after purchasing an additional 579 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Surmodics by 705.9% in the second quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $37,000 after buying an additional 1,080 shares during the period. Geode Capital Management LLC increased its position in shares of Surmodics by 0.3% during the second quarter. Geode Capital Management LLC now owns 336,239 shares of the company’s stock worth $9,992,000 after acquiring an additional 1,128 shares in the last quarter. Inspire Investing LLC raised its holdings in shares of Surmodics by 11.3% during the first quarter. Inspire Investing LLC now owns 11,250 shares of the company’s stock worth $343,000 after acquiring an additional 1,142 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Surmodics by 289.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company’s stock valued at $51,000 after acquiring an additional 1,286 shares in the last quarter. Institutional investors own 96.63% of the company’s stock.

Analysts Set New Price Targets

SRDX has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surmodics in a report on Wednesday, October 8th. Barrington Research reissued an “underperform” rating on shares of Surmodics in a research report on Friday, November 14th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $43.00.

Surmodics Price Performance

NASDAQ:SRDX opened at $42.98 on Friday. Surmodics, Inc. has a 52-week low of $25.87 and a 52-week high of $43.00. The company has a market cap of $614.53 million, a P/E ratio of -34.94 and a beta of 1.30. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.10 and a current ratio of 3.91. The stock’s 50-day simple moving average is $36.08 and its 200 day simple moving average is $33.49.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).